Johnson and Johnson (NYSE:Jnj) It is one of the stocks that Jim Cramer placed under the microscope. Cramer recalled his discussion with the company’s CEO and commented:
“What Else Might Work? Last friday on the show, we had Joaquin Duato. Lawsuits that they have, but i Believe the Risk from the Asbestos and the Baby Powder Litigation You have created as J & J’s Been Winning the Cases, and It’s Planning to Keep Fighting Them One by One.
Gil C/Shuttersock.com
Johnson & Johnson (NYSE: JNJ) develops pharmaceuticals and medical technologies that cover immunology, oncology, neuroscience, infectious diseases, cardiovascular care and pulmonary hypertension. In addition, the company provides surgical solutions, orthopedics, vision care and neurovascular products.
While we recognize JNJ’s potential as an investment, we believe that certain AI actions offer greater upward potential and have less down risk. If you are looking for an extremely undervalued action that also benefits significantly from the Trump era tariffs and the wave trend, see our free report on the The best short -term AI actions.
Read below: 30 actions that should double in 3 years and 11 hidden shares to buy right now.
Disclosure: None. This article is originally published in Internal monkey.
(Tagstotranslate) Johnson and Johnson (T) Jim Cramer (T) Joaquin Duato